ABSTRACT
While neurosurgical interventions are frequently used in laboratory mice, refinement efforts to optimize analgesic management based on multimodal approaches appear to be rather limited. Therefore, we compared the efficacy and tolerability of combinations of the non-steroidal anti-inflammatory drug carprofen, a sustained-release formulation of the opioid buprenorphine, and the local anesthetic bupivacaine with carprofen monotherapy. Female and male C57BL/6J mice were subjected to isoflurane anesthesia and an intracranial electrode implant procedure. Given the multidimensional nature of postsurgical pain and distress, various physiological, behavioral, and biochemical parameters were applied for their assessment. The analysis revealed alterations in Neuro scores, home cage locomotion, body weight, nest building, mouse grimace scales, and fecal corticosterone metabolites. A composite measure scheme allowed the allocation of individual mice to severity classes. The comparison between groups failed to indicate the superiority of multimodal regimens over high-dose NSAID monotherapy. In conclusion, our findings confirmed the informative value of various parameters for assessment of pain and distress following neurosurgical procedures in mice. While all drug regimens were well tolerated in control mice, our data suggest that the total drug load should be carefully considered for perioperative management. Future studies would be of interest to assess potential synergies of drug combinations with lower doses of carprofen.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal , Mice, Inbred C57BL , Neurosurgical Procedures , Pain Management , Pain, Postoperative , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Mice , Male , Pain Management/methods , Female , Pain, Postoperative/drug therapy , Neurosurgical Procedures/adverse effects , Carbazoles/administration & dosage , Analgesia/methods , Bupivacaine/administration & dosage , Buprenorphine/administration & dosage , Analgesics, Opioid/administration & dosage , Drug Therapy, CombinationABSTRACT
BACKGROUND/AIM: Randomized trials have shown the benefit of combining tyrosine kinase inhibitors (TKI) and chemotherapy in the treatment of epidermal growth factor receptor-mutant non-small-cell lung cancer (NSCLC). For anaplastic lymphoma kinase-rearranged (ALK+) NSCLC, prospective trial results of the combination are not available and have not even been thoroughly investigated in vitro. In this study, we investigated combinations of TKI and chemotherapy using in vitro models of ALK+ NSCLC. MATERIALS AND METHODS: ALK+ cell line models H3122, H2228, and DFCI032 with differing primary resistance to ALK receptor TKIs were used. We investigated short-(viability assay) and long-term (colony-formation assay) cytotoxicity, apoptosis, and cell signaling in response to the combinations of agents. We selected the most commonly used agents, alectinib, cisplatin, and pemetrexed, to investigate the combination effects. RESULTS: In the combination experiments with short-term exposure, synergism between TKI and pemetrexed was observed, while cisplatin had antagonistic effects. In the long-term experiments, the combination of cisplatin and TKI was synergistic in all lines, while no synergism was observed with pemetrexed. Among the chemotherapy and TKI sequences, cisplatin followed by TKI was more cytotoxic than the opposite in two out of the three models. In the TKI-sensitive H3122 cell line, the combination of chemotherapy and TKI combination increased apoptosis. Interestingly, pemetrexed treatment resulted in the activation of ALK, which was abolished with TKI. CONCLUSION: Combining TKI and chemotherapy in ALK+ models has some synergistic effects that overcome primary TKI resistance. However, the synergy varies depending on the chemotherapeutic agent, cytotoxic assay, and the cell line used. Prospective clinical trials are warranted to fully characterize the potential of combination chemotherapy with TKIs in ALK+ NSCLC.
Subject(s)
Anaplastic Lymphoma Kinase , Antineoplastic Combined Chemotherapy Protocols , Carcinoma, Non-Small-Cell Lung , Cisplatin , Lung Neoplasms , Pemetrexed , Protein Kinase Inhibitors , Humans , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Anaplastic Lymphoma Kinase/antagonists & inhibitors , Anaplastic Lymphoma Kinase/genetics , Anaplastic Lymphoma Kinase/metabolism , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Protein Kinase Inhibitors/pharmacology , Cell Line, Tumor , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/pharmacology , Cisplatin/administration & dosage , Pemetrexed/pharmacology , Pemetrexed/administration & dosage , Apoptosis/drug effects , Drug Synergism , Drug Resistance, Neoplasm/drug effects , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/metabolism , Piperidines/pharmacology , Piperidines/administration & dosage , Carbazoles/pharmacology , Carbazoles/administration & dosageABSTRACT
We present the case of a 34-year-old Japanese man with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, treatment with lorlatinib resulted in a good intracranial response. In this case, we investigated brain penetration ratio of brigatinib using cerebrospinal fluid and paired serum samples, and the ratio was 0.012. Further, we investigated resistance mechanisms via next-generation sequencing (NGS) using lung biopsy at lung cancer diagnosis and brain biopsy sample at progressive disease of brigatinib. No apparent resistance mechanism of known ALK resistance, such as ALK mutations, amplifications, epithelial-mesenchymal transition (EMT) and bypass pathway activation were detected. Taken together, we speculate that the low CNS penetration rate of brigatinib confers CNS progression. Further studies are warranted to reveal the resistance mechanism and propose a treatment strategy for CNS progression in ALK-positive patients.
Subject(s)
Adenocarcinoma of Lung , Aminopyridines , Anaplastic Lymphoma Kinase , Carbazoles , Drug Resistance, Neoplasm , Lactams, Macrocyclic , Lactams , Lung Neoplasms , Organophosphorus Compounds , Piperidines , Pyrazoles , Pyrimidines , Humans , Male , Organophosphorus Compounds/therapeutic use , Organophosphorus Compounds/pharmacology , Organophosphorus Compounds/administration & dosage , Lactams/therapeutic use , Adult , Aminopyridines/therapeutic use , Aminopyridines/pharmacology , Anaplastic Lymphoma Kinase/genetics , Pyrimidines/therapeutic use , Pyrimidines/pharmacology , Pyrimidines/administration & dosage , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lactams, Macrocyclic/therapeutic use , Lactams, Macrocyclic/pharmacology , Adenocarcinoma of Lung/drug therapy , Adenocarcinoma of Lung/pathology , Adenocarcinoma of Lung/genetics , Pyrazoles/therapeutic use , Pyrazoles/pharmacology , Carbazoles/therapeutic use , Carbazoles/pharmacology , Carbazoles/administration & dosage , Piperidines/therapeutic use , Piperidines/pharmacology , Brain Neoplasms/drug therapy , Brain Neoplasms/secondaryABSTRACT
Sofosbuvir (SOF) is a P-glycoprotein (P-gp) substrate, and carvedilol (CAR) is an inhibitor of P-gp, suggesting that it may affect the oral pharmacokinetics and safety of SOF. The current study investigated the pharmacokinetic interaction of CAR with SOF and its metabolite, GS-331007, and the possible consequent toxicities in rats. To assess the pharmacokinetics of SOF and GS-331007, rats were divided into three groups; all received a single oral dose of SOF preceded with saline (SAL), verapamil (VER) as a standard P-gp inhibitor, or CAR, respectively. The serosal, plasma, and hepatic tissue contents of SOF and GS-331007 were assessed using LC-MS/MS. Renal and hepatic toxicities were assessed using biochemical and histopathological tests. Serosal and plasma concentrations of SOF and GS-331007 were increased in the presence of CAR, suggesting a significant inhibitory effect of CAR on intestinal P-gp. Simultaneously, the pharmacokinetic profile of SOF showed a significant increase in the Cmax, AUC(0-t), AUC (0-∞), t1/2, and a reduction in its apparent oral clearance. While the pharmacokinetic profile of GS-331007 was not significantly affected. However, this notable elevation in drug oral bioavailability was corroborated by a significant alteration in renal functions. Hence, further clinical investigations are recommended to ensure the safety and dosing of CAR/SOF combination.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1 , Carvedilol , Drug Interactions , Sofosbuvir , Carvedilol/pharmacokinetics , Carvedilol/pharmacology , Carvedilol/administration & dosage , Animals , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , Male , Rats , Sofosbuvir/pharmacokinetics , Sofosbuvir/pharmacology , Sofosbuvir/administration & dosage , Rats, Sprague-Dawley , Verapamil/pharmacokinetics , Verapamil/pharmacology , Carbazoles/pharmacokinetics , Carbazoles/administration & dosage , Carbazoles/pharmacology , Area Under Curve , Propanolamines/pharmacokinetics , Propanolamines/administration & dosage , Propanolamines/pharmacology , Liver/metabolism , Liver/drug effects , Antiviral Agents/pharmacokinetics , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Kidney/metabolism , Kidney/drug effects , Administration, OralABSTRACT
Immunodeficient NSG mice are reported to be less responsive to buprenorphine analgesia. Here, we used NSG mice to compare the efficacy of the commonly used dose of carprofen (5 mg/kg) with 5 and 10 times that dose (25 and 50 mg/kg) for attenuating postoperative mechanical and thermal hypersensitivity following an incisional pain model. Male and female NSG mice (n = 45) were randomly assigned to one of 4 groups and received daily subcutaneous injections for 3 d: saline (5 mL/kg), 5 mg/kg carprofen (Carp5), 25 mg/kg carprofen (Carp25), and 50 mg/kg carprofen (Carp50). Mechanical and thermal hypersensitivity were assessed 24 h before and at 4, 24, and 48 h after surgery. Plasma carprofen concentrations were measured in a separate group of mice (n = 56) on days 0 (at 2, 4, 12, and 23 h), 1, and 2 after the first, second, and third doses, respectively. Toxicity was assessed through daily fecal occult blood testing (n = 27) as well as gross and histopathologic evaluation (n = 15). Our results indicated that the saline group showed both mechanical and thermal hypersensitivity throughout the study. Carp5 did not attenuate mechanical or thermal hypersensitivity at any time point. Carp25 attenuated mechanical and thermal (except for the 4-h time point) hypersensitivity. Carp50 attenuated only thermal hypersensitivity at 24 h. Fecal occult blood was detected in 1 of 8 Carp25-treated mice at 48 and 72 h. Histopathologic abnormalities (gastric ulceration, ulcerative enteritis, and renal lesions) were observed in some Carp50-treated mice. Plasma carprofen concentrations were dose and time dependent. Our results indicate that Carp25 attenuated postoperative mechanical and thermal hypersensitivity more effectively than Carp5 or Carp50 in NSG mice with incisional pain. Therefore, we recommend providing carprofen at 25 mg/kg SID for incisional pain procedures using immunodeficient NSG mouse.
Subject(s)
Carbazoles , Pain, Postoperative , Animals , Mice , Female , Pain, Postoperative/drug therapy , Pain, Postoperative/prevention & control , Male , Carbazoles/administration & dosage , Hyperalgesia/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Dose-Response Relationship, DrugABSTRACT
BACKGROUND/AIMS: Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration. The aim of this study was to investigate the beneficial effects of carvedilol-loaded stents on 2-year clinical outcomes after stent implantation in patients with coronary artery disease. METHODS: We performed a prospective trial with male subjects to compare the safety and effects of carvedilol-loaded BiodivYsio(R) stents implanted into 20 patients with those of bare-metal BiodivYsio(R) stents implanted into 21 patients for de novo coronary lesions. The primary end point was the degree of neointimal hyperplasia, which was measured by intravascular ultrasound (IVUS) 6 months after the procedure; the secondary end point was major adverse cardiac events (MACE) at 2 years after implantation. All carvedilol and control stents were deployed successfully. RESULTS: A 2-year follow-up was completed for 19 patients (95%) in the carvedilol stent group and 20 patients (95%) in the control stent group. IVUS showed a trend toward a larger luminal area (6.86 +/- 2.59 vs. 5.47 +/- 1.52 mm2, p = 0.267), smaller neointimal area (1.34 +/- 0.70 vs. 2.40 +/- 1.73 mm2, p = 0.18), and reduced net decrease in luminal area (-0.78 +/- 0.97 vs. -1.89 +/- 1.78 mm2, p = 0.106) in the carvedilol stent group compared with the control stent group, respectively. There were no significant differences in the incidence of MACE (10.5 vs. 30.0%, respectively, p = 0.132) between the groups at 2 years after stent implantation. Stent thrombosis did not occur in either group after 2 years. CONCLUSIONS: The carvedilol-loaded stents tended to inhibit neointimal hyperplasia without the occurrence of cardiac death, myocardial infarction, or stent thrombosis at 2-year follow-up.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Angioplasty, Balloon, Coronary , Carbazoles/administration & dosage , Coronary Artery Disease/therapy , Follow-Up Studies , Propanolamines/administration & dosage , Prospective Studies , Stents , Treatment Outcome , Ultrasonography, InterventionalABSTRACT
BACKGROUND: The relationship between the percentage of oxygen consumption reserve and percentage of heart rate reserve in heart failure patients either on non-optimized or off beta-blocker therapy is known to be unreliable. The aim of this study was to evaluate the relationship between the percentage of oxygen consumption reserve and percentage of heart rate reserve in heart failure patients receiving optimized and non-optimized beta-blocker treatment during a treadmill cardiopulmonary exercise test. METHODS: A total of 27 sedentary heart failure patients (86 percent male, 50±12 years) on optimized beta-blocker therapy with a left ventricle ejection fraction of 33±8 percent and 35 sedentary non-optimized heart failure patients (75 percent male, 47±10 years) with a left ventricle ejection fraction of 30±10 percent underwent the treadmill cardiopulmonary exercise test (Naughton protocol). Resting and peak effort values of both the percentage of oxygen consumption reserve and percentage of heart rate reserve were, by definition, 0 and 100, respectively. RESULTS: The heart rate slope for the non-optimized group was derived from the points 0.949±0.088 (0 intercept) and 1.055±0.128 (1 intercept), p<0.0001. The heart rate slope for the optimized group was derived from the points 1.026±0.108 (0 intercept) and 1.012±0.108 (1 intercept), p=0.47. Regression linear plots for the heart rate slope for each patient in the non-optimized and optimized groups revealed a slope of 0.986 (almost perfect) for the optimized group, but the regression analysis for the non-optimized group was 0.030 (far from perfect, which occurs at 1). CONCLUSION: The relationship between the percentage of oxygen consumption reserve and percentage of heart rate reserve in patients on optimized beta-blocker therapy was reliable, but this relationship was unreliable in non-optimized heart failure patients.
Subject(s)
Female , Humans , Male , Middle Aged , Adrenergic beta-Antagonists/administration & dosage , Carbazoles/administration & dosage , Heart Failure/drug therapy , Heart Rate/drug effects , Oxygen Consumption/drug effects , Propanolamines/administration & dosage , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Captopril/administration & dosage , Drug Therapy, Combination , Enalapril/administration & dosage , Exercise Test/drug effects , Heart Failure/physiopathology , Heart Rate/physiology , Losartan/administration & dosage , Oxygen Consumption/physiologyABSTRACT
OBJETIVOS: A inibição dos sistemas renina-angiotensina-aldosterona (SRAA) e sistema nervoso autônomo simpático aumentou a perspectiva de sobrevida desses pacientes, além de permitir substancial melhora na qualidade de vida. O objetivo deste trabalho foi avaliar a realidade do tratamento aplicado e seu impacto sobre a doença em pacientes acompanhados em um ambulatório especializado em insuficiência cardíaca(IC). MÉTODOS: Foram estudados 96 pacientes acompanhados no ambulatório de Insuficiência Cardíaca e Transplante do Instituto do Coração, do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP). Os dados foram coletados durante a consulta ambulatorial a partir de prontuário médico e exame clínico. A escolha dos pacientes foi aleatória. RESULTADOS: A maior parte dos pacientes encontrava-se em classe funcional II (42,3 por cento) e em estágio C de evolução (94,9 por cento). A prescrição médica para os pacientes foi bastante próxima do preconizado pelas diretrizes. Aproximadamente 95 por cento recebem inibidores do SRAA (inibidor de ECA - enalapril e captopril - ou antagonista dos receptores de angiotensina-losartan), enquanto 85 por cento dos pacientes recebem, além desses, agentes betabloqueadores (carvedilol). A dose média prescrita também se aproxima das utilizadas nos grandes estudos, e atinge mais de 60 por cento da dose máxima de cada medicação. Os dados hemodinâmicos encontrados mostram pacientes estáveis, apesar da intensidade da disfunção e do remodelamento ventricular destes. CONCLUSÃO: Pacientes portadores de IC acompanhados por equipe médica especializada têm prescrição médica mais próxima do preconizado. Esses pacientes, embora com características marcadas de gravidade da doença, conseguem estabilidade hemodinâmica e clínica com a otimização terapêutica adequada.
OBJECTIVES: The inhibition of the rennin-angiotensin-aldosterone system (RAAS) and sympathetic autonomous nervous system has increased the perspective of survival in these patients, as well as allowing the improvement of the quality of life. The aim of this study was to evaluate the reality of the treatment employed and its impact on the disease in patients followed at a specialized heart failure (HF) outpatient clinic. METHODS: A sample of 96 patients followed at the HF and Transplant Outpatient Clinic of Heart Institute of the University of São Paulo School of Medicine (InCor -HCFMUSP) were evaluated. The data were collected during the ambulatory consultation from the medical files and through physical examination. Patients were randomly selected for the study. RESULTS: Most of the patients were Functional Class II (42.3 percent) and evolution stage C (94.9 percent). The medical prescription given to the patients was quite similar to the one recommended by the directives. Approximately 95 percent of them received RAAS inhibitors (ACE inhibitor - enalapril and captopril - or angiotensin receptor antagonist - losartan), whereas 85 percent of the patients additionally received beta blockers (carvedilol). The mean dose prescribed was also similar to the one used in large studies and reached more than 60 percent of the maximum dose for each medication. The hemodynamic data show that patients were stable, despite the intensity of the dysfunction and ventricular remodeling observed in these patients. CONCLUSION: Patients with HF followed by a specialized medical team receive a medical prescription that is closer to the recommended one. These patients, despite the marked characteristics of disease severity, achieve hemodynamic and clinical stability with an adequate therapeutic optimization.
Subject(s)
Female , Humans , Male , Middle Aged , Adrenergic beta-Antagonists/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Carbazoles/administration & dosage , Heart Failure/drug therapy , Propanolamines/administration & dosage , Captopril/administration & dosage , Drug Therapy, Combination , Enalapril/administration & dosage , Losartan/administration & dosage , Severity of Illness IndexABSTRACT
OBJECTIVE: To assess the effects of carvedilol in patients with idiopathic dilated cardiomyopathy. METHODS: In a double-blind randomized placebo-controlled study, 30 patients (7 women) with functional class II and III heart failure were assessed. Their ages ranged from 28 to 66 years (mean of 43ñ9 years), and their left ventricular ejection fraction varied from 8 per cnet to 35 per cent. Carvedilol was added to the usual therapy of 20 patients; placebo was added to the usual therapy of 10 patients. The initial dose of carvedilol was 12.5 mg, which was increased weekly until it reached 75 mg/day, according to the patient's tolerance. Clinical assessment, electrocardiogram, echocardiogram, and radionuclide ventriculography were performed in the pretreatment phase, being repeated after 2 and 6 months of medication use. RESULTS: A reduction in heart rate (p=0.016) as well as an increase in left ventricular shortening fraction (p=0.02) and in left ventricular ejection fraction (p=0.017) occurred in the group using carvedilol as compared with that using placebo. CONCLUSION: Carvedilol added to the usual therapy for heart failure resulted in better heart function.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Adrenergic beta-Antagonists/pharmacology , Carbazoles/pharmacology , Cardiac Output, Low/drug therapy , Cardiomyopathy, Dilated/drug therapy , Heart Rate/drug effects , Stroke Volume/drug effects , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/therapeutic use , Carbazoles/administration & dosage , Carbazoles/therapeutic use , Cardiac Output, Low/etiology , Cardiomyopathy, Dilated/complications , Double-Blind Method , Heart Ventricles/drug effects , Norepinephrine/bloodABSTRACT
Se evaluó el uso del carvedilol en pacientes con insuficiencia cardíaca mediante un ensayo clínico a doble ciego, valorándose la fracción de eyección y la capacidad de ejercicio. Se incluyó a 33 pacientes, a 14 se les administró placebo y a 19 carvedilol. La fracción de eyección basal fue 26,2 por ciento y 22 por ciento (p< 0,11), el tiempo de ejercicio fue 9,5 minutos y 9 minutos (p< 0,73), para los grupos tratados con carvedilol y con placebo respectivamente. La fracción de eyección, al final del estudio, fue 34,5 por ciento y 24,5 por ciento para los pacientes tratados con carvedilol y placebo en cada caso (p< 0,03). El tiempo de ejrcicio aumentó significativamente, 13,8 minutos y 10,6 minutos (p< 0,02)
Subject(s)
Humans , Adult , Middle Aged , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic alpha-Antagonists/therapeutic use , Carbazoles/administration & dosage , Carbazoles/therapeutic use , Heart Failure/drug therapy , Heart Failure/therapy , Stroke Volume , Exercise , Placebos/administration & dosageABSTRACT
Se evaluó el uso del carvedilol en pacientes con insuficiencia cardíaca mediante un ensayo clínico a doble ciego, valorándose la fracción de eyección y la capacidad de ejercicio. Se incluyó a 33 pacientes, a 14 se les administró placebo y a 19 carvedilol. La fracción de eyección basal fue 26,2 por ciento y 22 por ciento (p< 0,11), el tiempo de ejercicio fue 9,5 minutos y 9 minutos (p< 0,73), para los grupos tratados con carvedilol y con placebo respectivamente. La fracción de eyección, al final del estudio, fue 34,5 por ciento y 24,5 por ciento para los pacientes tratados con carvedilol y placebo en cada caso (p< 0,03). El tiempo de ejrcicio aumentó significativamente, 13,8 minutos y 10,6 minutos (p< 0,02) (AU)
Subject(s)
Humans , Adult , Middle Aged , Heart Failure/drug therapy , Heart Failure/therapy , Stroke Volume , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic alpha-Antagonists/therapeutic use , Carbazoles/administration & dosage , Carbazoles/therapeutic use , Exercise , Placebos/administration & dosageABSTRACT
Mediante estudio clínico doble ciego se realizó la valoración del efecto sintomático de carprofeno y sulindac (ambos administrados por vía oral) en dos grupos de 15 pacientes cada uno con osteoartrosis de rodilla, cadera o ambas. Se tomaron como parámetros el dolor, medio mediante diversos procedimientos por el médico y el paciente; la rigidez articular subjetiva al iniciar la marcha postreposo; la valoración del estado reumático; y la aceptación del medicamento por el paciente. Se demostró superioridad clínica del efecto sintomático de carprofeno por la respuesta observada en los diferentes parámetros; la tolerancia al medicamento fue semejante en ambos compuestos
Subject(s)
Adult , Middle Aged , Humans , Male , Female , Carbazoles/administration & dosage , Carbazoles/therapeutic use , Hip Joint , Osteoarthritis/drug therapy , Clinical Trials as Topic , Double-Blind MethodABSTRACT
Mediante estudio doble ciego, se comparó el efecto sintomático de carprofeno y sulindac en pacientes con osteoartrosis de cadera, rodilla o ambas. Se analizan los resultados obtenidos para todos los síntomas relacionados con el proceso articular degenerativo: dolor en todas sus formas de manifestación y rigidez articular subjetiva; se hizo el registro con escalas de intensidad y escala visual analógica. Se consideraron también las opiniones globales del investigador y los pacientes así como la aparición de efectos indeseables. Se concluye que el efecto sintomático de carprofeno y sulindac es semejante aun cuando la analgesia total fue un suceso más común con el primero. La tolerancia fue muy superior en el grupo tratado con carprofeno registrándose efectos indeseables con una frecuencia tres veces mayor con sulindac que con carprofeno